MASS vs MASI vs PODD vs HOLX

For growth investors, Insulet Corporation (PODD) is the stronger pick with 30.

7% revenue growth year-over-year, versus -27. 1% for Masimo Corporation (MASI). 908 Devices Inc. (MASS) offers the better valuation at 15. 0x trailing P/E, making it the more compelling value choice. Analysts rate 908 Devices Inc. (MASS) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, 908 Devices Inc.

(MASS) is the cheapest at 15. 0x versus Insulet Corporation at 46. 1x. On forward P/E, Hologic, Inc. is actually cheaper at 17. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Hologic, Inc.

(HOLX) delivered a total return of +15. 8%, compared to -84. 0% for 908 Devices Inc. (MASS). Over 10 years, the gap is even starker: PODD returned +439. 0% versus MASS's -83. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Hologic, Inc.

(HOLX) is the lower-risk stock at 0. 41β versus 908 Devices Inc. 's 1. 38β — meaning MASS is approximately 236% more volatile than HOLX relative to the S&P 500. On balance sheet safety, 908 Devices Inc. (MASS) carries a lower debt/equity ratio of 12% versus 78% for Masimo Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Insulet Corporation (PODD) is pulling ahead at 30.

7% versus -27. 1% for Masimo Corporation (MASI). On earnings-per-share growth, the picture is similar: 908 Devices Inc. grew EPS 125. 5% year-over-year, compared to -39. 8% for Insulet Corporation. Over a 3-year CAGR, PODD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

908 Devices Inc.

(MASS) is the more profitable company, earning 34. 7% net margin versus -9. 9% for Masimo Corporation — meaning it keeps 34. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MASI leads at 20. 5% versus -70. 1% for MASS. At the gross margin level — before operating expenses — PODD leads at 71. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Hologic, Inc.

(HOLX) trades at 17. 2x forward P/E versus 32. 5x for Masimo Corporation — 15. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PODD: 111. 3% to $339. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Hologic, Inc.

(HOLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 41), +124. 3% 10Y return). Both have compounded well over 10 years (HOLX: +124. 3%, MASS: -83. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MASS is a small-cap deep-value stock; MASI is a small-cap quality compounder stock; PODD is a mid-cap high-growth stock; HOLX is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.